An industry article mentions Dasatinib as one of the most promising blockbuster drugs of 2006.

Rob

According to industry research, the introduction of high-potential pipeline products will grow the total market value of targeted therapies to $19.2 billion by 2014. Those products developed to inhibit multiple pathways show the most promise, particularly sorafenib and Bristol-Myers Squibb's (bms.com) dasatinib.

http://www.pharmalive.com/magazines/medad/view.cfm?articleID=2836


New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com

Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com

CML (Chronic Myelogenous Leukemia Support List)
---------------------------------
Part Of CMLHope.Com
An International Community Of CML Patients
For more information: http://cmlhope.com

Post Message: [email protected]
Subscribe:  [EMAIL PROTECTED]
Unsubscribe:  [EMAIL PROTECTED]
Change To No Mail/Web: [EMAIL PROTECTED]
Change To Digest: [EMAIL PROTECTED]
Change To Email: [EMAIL PROTECTED]
List Help: [EMAIL PROTECTED] 
CML Group Web Site http://groups.yahoo.com/group/CML




SPONSORED LINKS
Chronic myelogenous leukemia Leukemia treatment Cml


YAHOO! GROUPS LINKS




Reply via email to